Oncogenic PI3K deregulates transcription and translation
Top Cited Papers
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (12), 921-929
- https://doi.org/10.1038/nrc1753
Abstract
There have long been indications of a role for PI3K (phosphatidylinositol 3-kinase) in cancer pathogenesis. Experimental data document a requirement for deregulation of both transcription and translation in PI3K-mediated oncogenic transformation. The recent discoveries of cancer-specific mutations in PIK3CA, the gene that encodes the catalytic subunit p110α of PI3K, have heightened the interest in the oncogenic potential of this lipid kinase and have made p110α an ideal drug target.Keywords
This publication has 162 references indexed in Scilit:
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- In Situ Click Chemistry: Enzyme‐Generated Inhibitors of Carbonic Anhydrase IIAngewandte Chemie International Edition, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003
- Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancerInternational Journal of Cancer, 2003
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1Nature Cell Biology, 2002
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994